Nytt fimaBacc patent publisert
"fimaBacc" ruller framover
https://patents.justia.com/patent/20200268834
Publisert i går såvidt jeg kan se.
Tror ikke det er umulig at fimaBacc blir det fjerde benet, og vil bli nevnt allerede ved neste Q presentasjon. Fase 1 neste ?
https://patents.justia.com/patent/20200268834
Publisert i går såvidt jeg kan se.
Tror ikke det er umulig at fimaBacc blir det fjerde benet, og vil bli nevnt allerede ved neste Q presentasjon. Fase 1 neste ?
Redigert 20.01.2021 kl 06:34
Du må logge inn for å svare
Det er dessverre slik at leger skriver ut antibiotika som om de skulle fått betaling
Redigert 28.11.2020 kl 21:09
Du må logge inn for å svare
fabian2
27.11.2020 kl 19:53
2074
Merida er en super-kloking ! 50 kr sier han til Påske. Da får han 50% rett....fordi kursen er 100
Gjerne, men neppe 50kr til påske.
Mer som 30-35 men er penger det å,
Bare vi ikke ser 22 igjen, da blir det tvang salg frivillig.
Mer som 30-35 men er penger det å,
Bare vi ikke ser 22 igjen, da blir det tvang salg frivillig.
En grunn for oppgangen, noen leser ikke men selger basert på fest og ikke viten.
10 til 70 kommer. OSE mest spanande aksje vil jeg påstå.
PCI BIOTECH INTERIM Q3 2022 RESULTS
Highlights
Corporate
*Efforts to finance a Ph II clinical trial in head and neck cancer did not, under the current market conditions, result in a feasible way forward and the company reported in August that it will not conduct a company-sponsored Ph II trial with the fimaVacc technology. This entailed a downsizing of the clinical team, which is enacted during the second half of 2022, with full cost reduction effect in Q1 2023. The cash position of NOK 67 million per end of Q3 enables an estimated financial runway into 2024
*The company now focus its efforts and resources on non-clinical research, exploring new fields of use for the PCI technology platform utilising fimaNAc for dermatology and bioprocessing applications, and fimaVacc for intratumoural immunotherapy
fimaNAc – dermatology and bioprocessing
*The first step for the dermatology discovery project is to demonstrate fimaNAc-mediated nucleic acid delivery in a wound model. External feasibility experiments are contracted, with expected readout 1H 2023
*The bioprocessing discovery project exploring applications specifically suited to the strengths of the PCI technology has matured and is now focused on in-house experiments of fimaNAc for use in viral manufacturing
fimaVacc – intratumoural immunotherapy
*Exploring approaches aiming to identify novel immunotherapy treatment combinations with promising efficacy
fimaChem
10 til 70 kommer. OSE mest spanande aksje vil jeg påstå.
PCI BIOTECH INTERIM Q3 2022 RESULTS
Highlights
Corporate
*Efforts to finance a Ph II clinical trial in head and neck cancer did not, under the current market conditions, result in a feasible way forward and the company reported in August that it will not conduct a company-sponsored Ph II trial with the fimaVacc technology. This entailed a downsizing of the clinical team, which is enacted during the second half of 2022, with full cost reduction effect in Q1 2023. The cash position of NOK 67 million per end of Q3 enables an estimated financial runway into 2024
*The company now focus its efforts and resources on non-clinical research, exploring new fields of use for the PCI technology platform utilising fimaNAc for dermatology and bioprocessing applications, and fimaVacc for intratumoural immunotherapy
fimaNAc – dermatology and bioprocessing
*The first step for the dermatology discovery project is to demonstrate fimaNAc-mediated nucleic acid delivery in a wound model. External feasibility experiments are contracted, with expected readout 1H 2023
*The bioprocessing discovery project exploring applications specifically suited to the strengths of the PCI technology has matured and is now focused on in-house experiments of fimaNAc for use in viral manufacturing
fimaVacc – intratumoural immunotherapy
*Exploring approaches aiming to identify novel immunotherapy treatment combinations with promising efficacy
fimaChem
Redigert 23.01.2023 kl 07:09
Du må logge inn for å svare
fabian2
23.01.2023 kl 14:00
809
Dermatologi vet man de holder på med. Bioprocessing skjønner de fleste av oss moderat av. Du har nok rett i at akkurat aksjekursen plutselig kan få et voldsomt rykk oppover. Bare å vente på melding. Hausing og baissing er bare underholdning i mellomtiden